Fixed-dose combination antibiotics: the search for evidence using the example of ampicillin-cloxacillin. by Sayer, B et al.
S HO R T R E PO R T
Fixed-dose combination antibiotics: The search for evidence
using the example of ampicillin–cloxacillin
Ben Sayer1,2 | Barbara Bortone3 | Mike Sharland1 | Yingfen Hsia1,4
1Paediatric Infectious Disease Research Group,
St George's University of London, UK
2Newcastle Upon Tyne Hospitals NHS
Foundation Trust, UK
3Dipartimento di Scienze della Salute,
University of Florence UNIFI, Italy
4School of Pharmacy, Queen's University
Belfast, UK
Correspondence
Dr Yingfen Hsia, 97 Lisburn Road, Belfast BT9
7BL. UK.
Email: y.hsia@qub.ac.uk
High consumption of irrational fixed-dose combination (FDC) antibiotics may pose a
threat of antimicrobial resistance. In India, ampicillin–cloxacillin was the second
highest sold FDC antibiotic behind amoxicillin and clavulanic acid. There remain,
however, questions about its efficacy and safety and a lack of regulatory approval.
We undertook a literature review for ampicillin–cloxacillin to identify available data
on the safety and efficacy of its used as FDC. We identified 1071 studies for screen-
ing and 81 studies were considered for inclusion. Only 12 studies in English language
were accessible full texts for final review. None of the studies identified provided
strong evidence that ampicillin–cloxacillin differed in safety or efficacy to other treat-
ments used, and in particular to the component antibiotics used alone. To fully assess
the efficacy and safety of ampicillin–cloxacillin and other FDCs, a standardised search
format would be required. This should include broad international collaboration,
including contacting the relevant regulatory authorities to facilitate a more evidence-
based approach to their use.
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1 | INTRODUCTION
Emerging antimicrobial resistance (AMR) is a global public health cri-
sis. One major concern is high consumption of clinically irrational
fixed-dose combination (FDC) antibiotics, as it may potentially pose
a threat to tackling AMR,1 an issue identified as early as the
1960s.2 However, there remain limited data on FDC antibiotic use
at an international level. Determining the evidence for the use of
FDC antibiotics will be important for policy makers to strengthen
regulations for manufacturing these drugs. For example, India is 1 of
the largest consumers of antibiotics,3 and ampicillin–cloxacillin is the
second highest sold FDC antibiotic in this country.1 It is second only
to co-amoxiclav, 1 of the most commonly used FDC antibiotics
worldwide,4 an FDC comprising the penicillin class antibiotic amoxi-
cillin and clavulanic acid, a β-lactam class drug that combats AMR
by inhibiting bacterial β-lactamases.5 In contrast, ampicillin–cloxacil-
lin, when sold as an FDC contains 2 different functional antibiotics,
and has not been approved by the Central Drugs Standard Control
Organization (CDSCO) in India, the UK Medicines and Healthcare
Products Regulatory Agency, the European Medicines Agency or the
US Food and Drug Administration.1 Although ampicillin–cloxacillin
as FDC formulation has not been granted approval by many regula-
tory agencies, ampicillin and cloxacillin are listed separately in the
World Health Organization Model List of Essential Drugs. In India,
ampicillin and cloxacillin were approved by CDSCO in August 1965.
Dicloxacillin was approved by CDSCO in July 1978. In December
2006, CDSCO granted approval for ampicillin (250 mg) and
dicloxacillin (250 mg) as FDC formulation in India. It also needs to
be addressed that many FDCs are granted approvals by local
authorities not CDSCO in India. Although there is not a clear clinical
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reason for using ampicillin–cloxacillin as an FDC, its continued use
may be also related to the unavailability of cloxacillin independently
in India.6 In India and Nigeria, the use of this FDC has been
reported for intravenous antibiotic prophylaxis in surgery and by
oral or parenteral administration as empiric antibiotic therapy for
infectious diseases in adults and children.7,8 There remain, however,
questions about its efficacy and safety.
We undertook a literature review of papers for ampicillin–
cloxacillin with the primary objective of summarising available data on
the safety and efficacy of ampicillin–cloxacillin used as an FDC. A
secondary objective was to explore the feasibility and potential
challenges of systematically reviewing the safety and efficacy of FDC
antibiotics generally.
2 | METHODS
We searched the PubMed database in November 2018, without lan-
guage or date restrictions, using the terms “ampicillin AND cloxacillin”
for clinical studies of ampicillin–cloxacillin FDCs administered to
humans. Our broad search strategy aimed to be as inclusive as possi-
ble. We aimed to identify studies presenting data on efficacy or toxic-
ity of ampicillin–cloxacillin as an FDC in any population. We excluded
studies where ampicillin and cloxacillin were not used in FDCs,
reviews, news articles, pharmacokinetic studies, in vitro studies and
animal studies. We also searched ClinicalTrials.gov, the ISRCTN regis-
try and the World Health Organization International Clinical Trials
Registry to identify any ongoing clinical trials for this FDC. Single
screening of titles, abstracts and full text articles was carried out by
B.S., B.B. and Y.H.; if a reviewer was unsure of a study's eligibility,
another reviewer was consulted.
3 | RESULTS
We identified 15 studies with accessible full texts (open access or
available through our institutional library) with 1 further available
study identified from the reference list (Figure 1). A total of 12 papers
with accessible full texts were published in English. Ten papers were
published before 1980 and 2 after 2000.
F IGURE 1 Flow chart for
numbers of accessible abstracts
and full texts from PubMed
search for ampicillin–cloxacillin
What is already known about this subject
• Fixed-dose combination (FDC) antibiotics are being con-
sumed in large quantities in India, 1 of the highest con-
sumers of antibiotics worldwide.
• The inappropriate use of FDC antibiotics may be contrib-
uting to antimicrobial resistance.
• There is a lack of summarised international evidence to
support the use of FDC antibiotics.
What this study adds
• An insight into the lack of efficacy and safety evidence
for 1 of the most consumed FDC antibiotics in India,
ampicillin–cloxacillin.
• An overview of the difficulties such a search entails and
potential solutions for FDC antibiotic evaluation at
national and global level.
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One double-blind clinical trial from 1973 assessed ampicillin and
cloxacillin prophylactic use in oral, pharyngeal and laryngeal cancer
surgery.9 The double-blind study from 1973 compared ampicillin and
cloxacillin with a placebo in patients undergoing oral, laryngeal or
pharyngeal surgery for neoplastic lesions.9 The study reported the
frequency of postoperative wound and respiratory infections
to be higher among the placebo-treated patients (36 vs. 17%, P < .05
[no further statistical details given]) and did not report any untoward
effects from the FDC therapy. There were 2 randomised clinical trials
that utilised ampicillin–cloxacillin FDCs as prophylaxis in elective
caesarean sections, both published in the 2000s.10,11 There were lim-
ited data from the 2 most recent studies looking at its use as prophy-
laxis in caesarean sections, carried out in Nigeria10 and Sudan.11 The
Nigerian study compared a single dose of ceftriaxone with multiple
doses of a regimen comprising ampicillin–cloxacillin, gentamicin and
metronidazole,10 so the relative efficacy of ampicillin–cloxacillin used
alone could not be calculated. The study in Sudan compared a single
dose of ceftriaxone with 3 doses of ampicillin–cloxacillin and did not
find evidence of a difference in efficacy in preventing postoperative
infection; however, the number of events recorded was small.
There was also a single-blind randomised trial comparing
trimethoprim–sulfamethoxazole and ampiclox (ampicillin–cloxacillin in
FDC) in older patients with severe exacerbations of chronic bronchitis
that required hospitalization in 1970.12 The study included only
25 patients (12 receiving ampiclox and 13 receiving trimethoprim–
sulfamethoxazole); treatment failed for 1 patient in each group. One
case of sensitivity dermatitis was reported in the ampiclox group but
no further side effects were reported.12
A case series of children with septic arthritis in 1975 reported
good outcomes with a treatment regimen including oral ampicillin–
cloxacillin but did not include comparisons with other treatments and
did not specify whether it was used in an FDC.13 A separate case
series looked at the side effects of different antibiotic therapies and
the subsequent reported colitis and diarrhoea as a potential side
effect of their use in orthopaedic inpatients in London during a
19-month period in 1973–1974.14 Of 145 courses of ampicillin–
cloxacillin prescribed, 25 (17.2%) were associated with diarrhoea. This
was higher than reported for most of the other antibiotics and combi-
nations, including ampicillin alone (4/42, 9.5%). Four of the full texts
accessed were case reports15–18; these papers looked at the use of
ampicillin and cloxacillin in a series of different contexts and for differ-
ent populations, with some unclear as to whether it was used as an
FDC so it is very difficult to draw firm conclusions from these.
One additional paper was identified from the reference lists of
the screened studies.19 This randomized, prospective study compared
the efficacy of cefamandole naftate with a combination of ampicillin
and cloxacillin as prophylaxis in cardiac surgery in 1982.20 They
reported the overall rate of infection to be lower for the group given
cefamandole instead of ampicillin and cloxacillin (total infections equal
to 1.7% for the group given cefamandole and 13.7% for the group
given ampicillin plus cloxacillin).20
None of these studies provided strong evidence that ampicillin–
cloxacillin differed in safety or efficacy to the other treatments used,
and in particular to the component antibiotics used alone. However,
difficulties interpreting the results of these studies include a lack of
clarity as to whether ampicillin–cloxacillin was administered as an FDC
or as separate drugs13; presentation of data for the ampicillin–
cloxacillin group combined with other treatments10; publication before
the development of reporting standards for trials and observational
studies; and lack of comparison groups in case series and case reports.
Of the 66 papers considered for full text screening but not avail-
able as full text, 40 had abstracts available (30 in English and 10 in
other languages: 4 in Japanese, 3 in French, 1 in German, 1 in Italian
and 1 in Norwegian). A further 8 studies in Japanese did not have
abstracts available and were mostly published in the Japanese Journal
of Antibiotics. A further 6 potentially informative studies were in Ital-
ian, of which neither abstract nor full text were available in English,
4 German, 3 French (2 only abstracts and 1 unavailable) amongst sev-
eral others including Norwegian, Thai and Russian. None of these
papers appeared to report randomized–controlled trials.
Our search of clinical trials registries identified 1 potentially rele-
vant ongoing study: an open label trial comparing ampicillin–cloxacillin
and ceftriaxone for empirical treatment of infective endocarditis in a
hospital in Japan, although it is not explicitly stated that ampicillin–
cloxacillin is given as an FDC.21
4 | DISCUSSION
Given the high levels of use of antibiotic FDCs such as ampicillin–
cloxacillin, including in the absence of relevant regulatory approvals,3
it is critical to evaluate their efficacy and safety. Our literature review
highlights the paucity of the literature in 1 of the most commonly
used FDCs. It is unclear from the available data for which indications
most FDCs are being used.
Although we did not aim to review the use of ampicillin–cloxacillin
in routine practice, the studies identified were conducted in very spe-
cific indications, such as surgical prophylaxis and may not reflect the
indications for which this FDC is used more generally (e.g. more com-
mon clinical scenarios such as skin and soft tissue infections). There are
also very limited data in the older studies of the rationale for the dosing
regimen used, while a range of dosing regimens may be available for
the FDC in different countries. Most commonly, no formal safety data
have been submitted for registration to the relevant competent
authorities and, as no summary of product characteristics is available,
this has not been updated regularly as new data have been published.
This literature review also highlights difficulties in accessing some
potentially informative literature, particularly older studies and those
published in non-English language journals. Searching of other
databases may also have yielded further results. In addition, national
regulatory agencies may have access to further efficacy and safety
data submitted by manufacturers applying for regulatory approval,
which must also be considered in any assessment of the utility of
antibiotic FDCs.
Despite the lack of evidence on FDC antibiotics, there is a need
for appropriate FDC formulation for treatment. In 2018, the Indian
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government took a courageous decision to ban 328 FDCs in the
Indian market. Their determination to tighten regulation on inappro-
priate FDC formulations is a role model for other countries to fol-
low.22 It is important to strengthen regulatory system to manufacture
appropriate FDCs for clinical treatment.
5 | CONCLUSION
To fully assess the efficacy and safety of ampicillin–cloxacillin and
other FDCs, a standardised search format, including data on current
use, efficacy, dosing and safety, would be required for both national
and international approaches. In addition, prospective and retrospec-
tive evaluation of evidence is needed at each national level. The ratio-
nale for using FDC antibiotics should be further explored and require
studies to assess their efficacy, safety, and potential to accelerate
antimicrobial resistant. This should include broad international collab-
oration, including contacting the relevant international regulatory
authorities. Furthermore, international initiatives are needed to regu-
late the manufacturing and sales of these antibiotics. The next step
would be an assessment of the most frequently used FDCs interna-
tionally and the development of a common protocol for their formal
assessment.
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